These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 10681230)

  • 1. Nephropathy in type 2 diabetes.
    Mora C; Garcia J; Navarro JF
    N Engl J Med; 2000 Feb; 342(6):441; author reply 442. PubMed ID: 10681230
    [No Abstract]   [Full Text] [Related]  

  • 2. Tumor necrosis factor-alpha as a therapeutic target for diabetic nephropathy.
    Navarro-González JF; Jarque A; Muros M; Mora C; García J
    Cytokine Growth Factor Rev; 2009 Apr; 20(2):165-73. PubMed ID: 19251467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial.
    Navarro JF; Mora C; Muros M; García J
    J Am Soc Nephrol; 2005 Jul; 16(7):2119-26. PubMed ID: 15917336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction of macroalbuminuria with pentoxifylline in diabetic nephropathy. Report of three cases.
    Gorson DM
    Diabetes Care; 1998 Dec; 21(12):2190-1. PubMed ID: 9839116
    [No Abstract]   [Full Text] [Related]  

  • 5. Diabetic nephropathy: renoprotective effects of pentoxifylline in the PREDIAN trial.
    He T; Cooper ME
    Nat Rev Nephrol; 2014 Oct; 10(10):547-8. PubMed ID: 25201141
    [No Abstract]   [Full Text] [Related]  

  • 6. Association between tumour necrosis factor-alpha G-308A polymorphism and risk of nephropathy in obese Chinese type 2 diabetic patients.
    Wang Y; Ng MC; So WY; Ma R; Ko GT; Tong PC; Chan JC
    Nephrol Dial Transplant; 2005 Dec; 20(12):2733-8. PubMed ID: 16141456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiproteinuric effect of pentoxifylline in patients with diabetic nephropathy.
    Navarro JF; Mora C
    Diabetes Care; 1999 Jun; 22(6):1006-8. PubMed ID: 10372263
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of pentoxifylline on proteinuria in normotensive patients with diabetes mellitus.
    White JR; Karam JH; Koda-Kimble MA
    DICP; 1990 Nov; 24(11):1043-5. PubMed ID: 2275224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is pentoxifylline the drug of the decade?
    Ely H
    J Am Acad Dermatol; 1994 Apr; 30(4):639-42. PubMed ID: 8157792
    [No Abstract]   [Full Text] [Related]  

  • 10. Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration.
    Navarro JF; Milena FJ; Mora C; León C; García J
    Am J Nephrol; 2006; 26(6):562-70. PubMed ID: 17167242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated levels of interleukin-18 and tumor necrosis factor-alpha in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy.
    Moriwaki Y; Yamamoto T; Shibutani Y; Aoki E; Tsutsumi Z; Takahashi S; Okamura H; Koga M; Fukuchi M; Hada T
    Metabolism; 2003 May; 52(5):605-8. PubMed ID: 12759891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Losartan in diabetic nephropathy.
    Perico N; Ruggenenti P; Remuzzi G
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):473-83. PubMed ID: 15225108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of renal involvement on peripheral blood mononuclear cell expression behaviour of tumour necrosis factor-alpha and interleukin-6 in type 2 diabetic patients.
    Navarro JF; Mora C; Gómez M; Muros M; López-Aguilar C; García J
    Nephrol Dial Transplant; 2008 Mar; 23(3):919-26. PubMed ID: 17911088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetic nephropathy: introduction.
    Breyer MD
    Semin Nephrol; 2007 Mar; 27(2):129. PubMed ID: 17418681
    [No Abstract]   [Full Text] [Related]  

  • 15. Adequate vascular repair is relevant to improving renal perfusion and function following vasodilators in normoalbuminuric type 2 diabetic nephropathy.
    Futrakul N; Futrakul P
    Am J Kidney Dis; 2009 Sep; 54(3):583-4. PubMed ID: 19700066
    [No Abstract]   [Full Text] [Related]  

  • 16. Increased serum levels of interleukin-18 in patients with diabetic nephropathy.
    Mahmoud RA; el-Ezz SA; Hegazy AS
    Ital J Biochem; 2004 Jul; 53(2):73-81. PubMed ID: 15646011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetic neuropathy in type 1 and type 2 diabetes and the effects of C-peptide.
    Sima AA
    J Neurol Sci; 2004 May; 220(1-2):133-6. PubMed ID: 15140622
    [No Abstract]   [Full Text] [Related]  

  • 18. [Diabetes mellitus, hypertension and kidney].
    Monhart V
    Vnitr Lek; 2008 May; 54(5):499-504, 507. PubMed ID: 18630636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy.
    Rysz J; Banach M; Stolarek RA; Pasnik J; Cialkowska-Rysz A; Koktysz R; Piechota M; Baj Z
    J Nephrol; 2007; 20(4):444-52. PubMed ID: 17879211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antihypertensive treatment in type II diabetes and diabetic nephropathy].
    Chantrel F; Bouiller M; Kolb I; Hannedouche T
    Nephrologie; 2000; 21(2):47-55. PubMed ID: 10798204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.